{"name":"Shanghai Mental Health Center","slug":"shanghai-mental-health-center","ticker":"","exchange":"","domain":"smhc.org.cn","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":25,"colorKey":"oncology","drugs":[{"name":"Augment with Aripiprazole","genericName":"Augment with Aripiprazole","slug":"augment-with-aripiprazole","indication":"Augmentation therapy for major depressive disorder (Phase 2 indication)","status":"phase_2"},{"name":"Donepezil and Lithium","genericName":"Donepezil and Lithium","slug":"donepezil-and-lithium","indication":"Alzheimer's disease with mood disturbance or bipolar features","status":"marketed"},{"name":"Intramuscular Haloperidol","genericName":"Intramuscular Haloperidol","slug":"intramuscular-haloperidol","indication":"Acute agitation and psychosis","status":"phase_3"},{"name":"Lithium Carbonate Pill","genericName":"Lithium Carbonate Pill","slug":"lithium-carbonate-pill","indication":"Bipolar disorder, manic episodes","status":"marketed"},{"name":"Lithium+fluvoxamine","genericName":"Lithium+fluvoxamine","slug":"lithium-fluvoxamine","indication":"Treatment-resistant depression","status":"marketed"},{"name":"Perospirone hydrochloride tablets","genericName":"Perospirone hydrochloride tablets","slug":"perospirone-hydrochloride-tablets","indication":"Schizophrenia","status":"marketed"},{"name":"Phase 1: Perphenazine","genericName":"Phase 1: Perphenazine","slug":"phase-1-perphenazine","indication":"Schizophrenia","status":"phase_3"},{"name":"Phase 1: Risperidone","genericName":"Phase 1: Risperidone","slug":"phase-1-risperidone","indication":"Schizophrenia","status":"phase_3"},{"name":"Phase 2: Olanzapine","genericName":"Phase 2: Olanzapine","slug":"phase-2-olanzapine","indication":"Schizophrenia","status":"phase_3"},{"name":"toludesvenlafaxine hydrochloride sustained-release tablets","genericName":"toludesvenlafaxine hydrochloride sustained-release tablets","slug":"toludesvenlafaxine-hydrochloride-sustained-release-tablets","indication":"Major depressive disorder","status":"marketed"},{"name":"Anyu Peibo","genericName":"Anyu Peibo","slug":"anyu-peibo","indication":"Major depressive disorder","status":"phase_3"},{"name":"Augment with Memantine","genericName":"Augment with Memantine","slug":"augment-with-memantine","indication":"Moderate to severe Alzheimer's disease","status":"phase_2"},{"name":"Innovator Escitalopram","genericName":"Innovator Escitalopram","slug":"innovator-escitalopram","indication":"Major depressive disorder","status":"phase_2"},{"name":"Lithium carbonate + perospirone hydrochloride","genericName":"Lithium carbonate + perospirone hydrochloride","slug":"lithium-carbonate-perospirone-hydrochloride","indication":"Bipolar disorder (acute and maintenance treatment)","status":"marketed"},{"name":"Mirtazapine/SNRIs","genericName":"Mirtazapine/SNRIs","slug":"mirtazapine-snris","indication":"Major depressive disorder","status":"marketed"},{"name":"Phase 1: Amisulpride","genericName":"Phase 1: Amisulpride","slug":"phase-1-amisulpride","indication":"Schizophrenia","status":"phase_3"},{"name":"Phase 1: Aripiprazole","genericName":"Phase 1: Aripiprazole","slug":"phase-1-aripiprazole","indication":"Schizophrenia","status":"phase_3"},{"name":"Phase 1: Olanzapine","genericName":"Phase 1: Olanzapine","slug":"phase-1-olanzapine","indication":"Schizophrenia","status":"phase_3"},{"name":"Phase 2: Amisulpride","genericName":"Phase 2: Amisulpride","slug":"phase-2-amisulpride","indication":"Schizophrenia","status":"phase_3"},{"name":"Phase 2: Clozapine","genericName":"Phase 2: Clozapine","slug":"phase-2-clozapine","indication":"Treatment-resistant schizophrenia","status":"phase_3"},{"name":"Phase 3B: Clozapine or another SGAs","genericName":"Phase 3B: Clozapine or another SGAs","slug":"phase-3b-clozapine-or-another-sgas","indication":"Schizophrenia","status":"phase_3"},{"name":"Placebo plus Lithium","genericName":"Placebo plus Lithium","slug":"placebo-plus-lithium","indication":"Bipolar disorder (acute mania and maintenance treatment)","status":"marketed"},{"name":"fluoxetine + Amfebutamone","genericName":"fluoxetine + Amfebutamone","slug":"fluoxetine-amfebutamone","indication":"Major depressive disorder","status":"marketed"},{"name":"placebo with Clozapine","genericName":"placebo with Clozapine","slug":"placebo-with-clozapine","indication":"Schizophrenia, particularly treatment-resistant cases","status":"marketed"},{"name":"sodium valproate with Clozapine","genericName":"sodium valproate with Clozapine","slug":"sodium-valproate-with-clozapine","indication":"Schizophrenia (treatment-resistant or acute exacerbation)","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"immunology","drugs":[{"name":"Dayingpian","genericName":"Dayingpian","slug":"dayingpian","indication":"Other","status":"phase_2"},{"name":"Lemborexant tablets","genericName":"Lemborexant tablets","slug":"lemborexant-tablets","indication":"Insomnia","status":"phase_2"},{"name":"Octohydroaminoacridine Succinate","genericName":"Octohydroaminoacridine Succinate","slug":"octohydroaminoacridine-succinate","indication":"Cognitive impairment or dementia (likely indication based on mechanism and phase 3 status)","status":"phase_3"},{"name":"Orcinoside","genericName":"Orcinoside","slug":"orcinoside","indication":"Other","status":"phase_2"},{"name":"Yuxintine","genericName":"Yuxintine","slug":"yuxintine","indication":"Other","status":"phase_2"},{"name":"amisulpride with Clozapine","genericName":"amisulpride with Clozapine","slug":"amisulpride-with-clozapine","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Augment with Aripiprazole","genericName":"Augment with Aripiprazole","slug":"augment-with-aripiprazole","phase":"phase_2","mechanism":"Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors that modulates dopaminergic and serotonergic neurotransmission in the brain.","indications":["Augmentation therapy for major depressive disorder (Phase 2 indication)","Schizophrenia and schizoaffective disorder (established indication for aripiprazole)"],"catalyst":""},{"name":"Donepezil and Lithium","genericName":"Donepezil and Lithium","slug":"donepezil-and-lithium","phase":"marketed","mechanism":"Donepezil inhibits acetylcholinesterase to increase acetylcholine levels in the brain, while lithium modulates intracellular signaling pathways and neuroprotection.","indications":["Alzheimer's disease with mood disturbance or bipolar features","Cognitive impairment with mood instability"],"catalyst":""},{"name":"Intramuscular Haloperidol","genericName":"Intramuscular Haloperidol","slug":"intramuscular-haloperidol","phase":"phase_3","mechanism":"Haloperidol is a typical antipsychotic that blocks dopamine D2 receptors in the brain to reduce psychotic symptoms and agitation.","indications":["Acute agitation and psychosis","Schizophrenia","Bipolar disorder with acute mania"],"catalyst":""},{"name":"Lithium Carbonate Pill","genericName":"Lithium Carbonate Pill","slug":"lithium-carbonate-pill","phase":"marketed","mechanism":"Lithium carbonate modulates intracellular signaling pathways, particularly inhibiting inositol monophosphatase and glycogen synthase kinase-3 (GSK-3), which stabilizes mood and reduces manic and depressive episodes.","indications":["Bipolar disorder, manic episodes","Bipolar disorder, maintenance treatment","Major depressive disorder, augmentation therapy"],"catalyst":""},{"name":"Lithium+fluvoxamine","genericName":"Lithium+fluvoxamine","slug":"lithium-fluvoxamine","phase":"marketed","mechanism":"Lithium enhances mood stabilization through effects on intracellular signaling, while fluvoxamine increases serotonin availability by inhibiting its reuptake, together targeting mood disorders through complementary neurochemical pathways.","indications":["Treatment-resistant depression","Bipolar disorder (depression phase)","Major depressive disorder with augmentation"],"catalyst":""},{"name":"Perospirone hydrochloride tablets","genericName":"Perospirone hydrochloride tablets","slug":"perospirone-hydrochloride-tablets","phase":"marketed","mechanism":"Perospirone is an atypical antipsychotic that blocks dopamine D2 receptors and serotonin 5-HT2A receptors in the brain.","indications":["Schizophrenia","Acute agitation in psychotic disorders"],"catalyst":""},{"name":"Phase 1: Perphenazine","genericName":"Phase 1: Perphenazine","slug":"phase-1-perphenazine","phase":"phase_3","mechanism":"Perphenazine is a typical antipsychotic that blocks dopamine D2 receptors in the brain to reduce psychotic symptoms.","indications":["Schizophrenia","Psychotic disorders","Severe nausea and vomiting"],"catalyst":""},{"name":"Phase 1: Risperidone","genericName":"Phase 1: Risperidone","slug":"phase-1-risperidone","phase":"phase_3","mechanism":"Risperidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.","indications":["Schizophrenia","Bipolar disorder (acute mania)","Irritability associated with autism spectrum disorder"],"catalyst":""},{"name":"Phase 2: Olanzapine","genericName":"Phase 2: Olanzapine","slug":"phase-2-olanzapine","phase":"phase_3","mechanism":"Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.","indications":["Schizophrenia","Bipolar I disorder (acute mania and maintenance)","Treatment-resistant depression (adjunctive)"],"catalyst":""},{"name":"toludesvenlafaxine hydrochloride sustained-release tablets","genericName":"toludesvenlafaxine hydrochloride sustained-release tablets","slug":"toludesvenlafaxine-hydrochloride-sustained-release-tablets","phase":"marketed","mechanism":"Toludesvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases synaptic levels of serotonin and norepinephrine by blocking their reuptake at the presynaptic membrane.","indications":["Major depressive disorder","Generalized anxiety disorder"],"catalyst":""},{"name":"Anyu Peibo","genericName":"Anyu Peibo","slug":"anyu-peibo","phase":"phase_3","mechanism":"Anyu Peibo is a medication used to treat depression.","indications":["Major depressive disorder"],"catalyst":""},{"name":"Augment with Memantine","genericName":"Augment with Memantine","slug":"augment-with-memantine","phase":"phase_2","mechanism":"Augment with Memantine is a combination of a glutamate receptor antagonist and a NMDA receptor antagonist, which may help to improve cognitive function in patients with Alzheimer's disease.","indications":["Moderate to severe Alzheimer's disease"],"catalyst":""},{"name":"Dayingpian","genericName":"Dayingpian","slug":"dayingpian","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Innovator Escitalopram","genericName":"Innovator Escitalopram","slug":"innovator-escitalopram","phase":"phase_2","mechanism":"Selective serotonin reuptake inhibitor","indications":["Major depressive disorder","Generalized anxiety disorder"],"catalyst":""},{"name":"Lemborexant tablets","genericName":"Lemborexant tablets","slug":"lemborexant-tablets","phase":"phase_2","mechanism":"Treats insomnia by modulating orexin receptors","indications":["Insomnia"],"catalyst":""},{"name":"Lithium carbonate + perospirone hydrochloride","genericName":"Lithium carbonate + perospirone hydrochloride","slug":"lithium-carbonate-perospirone-hydrochloride","phase":"marketed","mechanism":"Lithium carbonate modulates intracellular signaling pathways to stabilize mood, while perospirone hydrochloride acts as an atypical antipsychotic by blocking dopamine and serotonin receptors.","indications":["Bipolar disorder (acute and maintenance treatment)","Schizophrenia with mood symptoms"],"catalyst":""},{"name":"Mirtazapine/SNRIs","genericName":"Mirtazapine/SNRIs","slug":"mirtazapine-snris","phase":"marketed","mechanism":"Mirtazapine is a tetracyclic antidepressant that blocks alpha-2 adrenergic receptors and serotonin 5-HT2 and 5-HT3 receptors, increasing norepinephrine and serotonin neurotransmission.","indications":["Major depressive disorder","Anxiety disorders","Insomnia (off-label)"],"catalyst":""},{"name":"Octohydroaminoacridine Succinate","genericName":"Octohydroaminoacridine Succinate","slug":"octohydroaminoacridine-succinate","phase":"phase_3","mechanism":"Octohydroaminoacridine succinate is a cognitive enhancer that likely increases acetylcholine levels in the brain by inhibiting acetylcholinesterase.","indications":["Cognitive impairment or dementia (likely indication based on mechanism and phase 3 status)"],"catalyst":""},{"name":"Orcinoside","genericName":"Orcinoside","slug":"orcinoside","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Phase 1: Amisulpride","genericName":"Phase 1: Amisulpride","slug":"phase-1-amisulpride","phase":"phase_3","mechanism":"Amisulpride is a selective dopamine D2 and D3 receptor antagonist that blocks dopamine signaling in the brain to reduce psychotic symptoms and improve mood.","indications":["Schizophrenia","Psychotic disorders","Major depressive disorder with psychotic features"],"catalyst":""},{"name":"Phase 1: Aripiprazole","genericName":"Phase 1: Aripiprazole","slug":"phase-1-aripiprazole","phase":"phase_3","mechanism":"Aripiprazole is a dopamine D2/D3 receptor partial agonist that modulates dopaminergic and serotonergic neurotransmission in the brain.","indications":["Schizophrenia","Bipolar I disorder (acute manic or mixed episodes)","Major depressive disorder (adjunctive treatment)","Autism spectrum disorder (irritability)"],"catalyst":""},{"name":"Phase 1: Olanzapine","genericName":"Phase 1: Olanzapine","slug":"phase-1-olanzapine","phase":"phase_3","mechanism":"Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.","indications":["Schizophrenia","Bipolar I disorder (acute mania and maintenance treatment)","Treatment-resistant depression (as adjunctive therapy)"],"catalyst":""},{"name":"Phase 2: Amisulpride","genericName":"Phase 2: Amisulpride","slug":"phase-2-amisulpride","phase":"phase_3","mechanism":"Amisulpride is a selective dopamine D2 and D3 receptor antagonist that blocks dopamine signaling in the brain to reduce psychotic symptoms and improve mood.","indications":["Schizophrenia","Psychotic disorders","Major depressive disorder with psychotic features"],"catalyst":""},{"name":"Phase 2: Clozapine","genericName":"Phase 2: Clozapine","slug":"phase-2-clozapine","phase":"phase_3","mechanism":"Clozapine is an atypical antipsychotic that blocks dopamine D2 receptors and serotonin 5-HT2A receptors in the brain.","indications":["Treatment-resistant schizophrenia","Reduction of suicidal behavior in schizophrenia or schizoaffective disorder"],"catalyst":""},{"name":"Phase 3B: Clozapine or another SGAs","genericName":"Phase 3B: Clozapine or another SGAs","slug":"phase-3b-clozapine-or-another-sgas","phase":"phase_3","mechanism":"Clozapine and other second-generation antipsychotics block dopamine and serotonin receptors in the brain to reduce psychotic symptoms and improve mood regulation.","indications":["Schizophrenia","Treatment-resistant schizophrenia","Bipolar disorder","Psychotic disorders"],"catalyst":""},{"name":"Placebo plus Lithium","genericName":"Placebo plus Lithium","slug":"placebo-plus-lithium","phase":"marketed","mechanism":"Lithium modulates intracellular signaling pathways, particularly inhibiting glycogen synthase kinase-3 (GSK-3) and affecting monoamine neurotransmitter systems to stabilize mood.","indications":["Bipolar disorder (acute mania and maintenance treatment)","Major depressive disorder (augmentation therapy)","Suicidal behavior prevention in mood disorders"],"catalyst":""},{"name":"Yuxintine","genericName":"Yuxintine","slug":"yuxintine","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"amisulpride with Clozapine","genericName":"amisulpride with Clozapine","slug":"amisulpride-with-clozapine","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"fluoxetine + Amfebutamone","genericName":"fluoxetine + Amfebutamone","slug":"fluoxetine-amfebutamone","phase":"marketed","mechanism":"This combination enhances monoamine neurotransmission by inhibiting serotonin reuptake (fluoxetine) and inhibiting norepinephrine and dopamine reuptake (amfebutamone).","indications":["Major depressive disorder","Treatment-resistant depression"],"catalyst":""},{"name":"placebo with Clozapine","genericName":"placebo with Clozapine","slug":"placebo-with-clozapine","phase":"marketed","mechanism":"Clozapine is an atypical antipsychotic that blocks dopamine and serotonin receptors in the brain to reduce psychotic symptoms.","indications":["Schizophrenia, particularly treatment-resistant cases","Schizoaffective disorder","Reduction of suicidal behavior in schizophrenia"],"catalyst":""},{"name":"sodium valproate with Clozapine","genericName":"sodium valproate with Clozapine","slug":"sodium-valproate-with-clozapine","phase":"marketed","mechanism":"This combination pairs sodium valproate (a histone deacetylase inhibitor and GABA enhancer) with clozapine (an atypical antipsychotic) to provide synergistic effects on mood stabilization and antipsychotic activity.","indications":["Schizophrenia (treatment-resistant or acute exacerbation)","Bipolar disorder with psychotic features"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQMjAyTzdaTUdhX3dUamVyREhQM2ZXQU1WVTRZQThSYWVKT2I5ekFfS0tfRlFJR0NQZkhTOHhIY3FIcXRNRVNCYnhFS2hUSGUyY21IZ3hsNVFFX1NQcUdqd291OXZpQXdqdjd1eDBNYWZUU1ZBRXpzVVMtTWtoZzV3U19yeHNIX1BQeVlGNV9FYzhHNURTb1FFbllmMGVLWlJaQkdHNHVFcVF1Zko3OC1aUkVvZFpvT2ZZTGpRZEp5Vmt1UQ?oc=5","date":"2026-02-05","type":"pipeline","source":"Reuters","summary":"China launches new crackdown on medical insurance fraud - Reuters","headline":"China launches new crackdown on medical insurance fraud","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOc1lrRFFYSU5QeC1TczI3T3BXOFp0aXpaWktlUXRuUklGd0JuekJKUGpvNjg0R256V25iZnpxR2FIaE9adlJFalFfVWx2aW5VSmtXME9oZnk0MUtrZkM2Mmpoa2Y0dHFZM0RtdVFQQVZXcWxRQks0WVctaXM1bTZFVEpyUnRkYURKYzZhNUVnVDJrMExyWWlDZFBGUDRhUQ?oc=5","date":"2026-01-22","type":"pipeline","source":"Sixth Tone","summary":"Overdoing It: The Cheap Pain Pills Hooking Young Chinese - Sixth Tone","headline":"Overdoing It: The Cheap Pain Pills Hooking Young Chinese","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPS19xeWxLMFNUN29xNEFfbVBqUmxHRGhrV0J0N1ZJWUhKUmhuUUpQZEY0alhDdlF1WVlxUUtKU2hVM05ycFNVWVhjZHRFZlBhVkVScFRfMEtyNzhuVVZQeGNpN1VXbTE0QXBhc1BkVUJfUWJaRi1kaW90SVRqSkRpQU5wMVI2aHhJZ1VINHZ1dmtUZzJwanM4ajJfdXMycEpXX2c?oc=5","date":"2025-09-29","type":"trial","source":"Medscape","summary":"Novel SNRI Promising for Major Depression: Phase 2 Data - Medscape","headline":"Novel SNRI Promising for Major Depression: Phase 2 Data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPQTNjQkpFVEVRN2xpRWs4ajRlMHpZN0lBZ3V6WGRDQUhtblNwVy1qSHUtUXRwOHVDMEFGYUdWQ3N4SGRXX2UwemdVT19PWW15MU1jN0ZHMFE5TUltQTdWOGxKdmtra2tPSFByY0xlUk05V3hwS3g4YkNTNlBoM3lfOTdYdWdKMm9KaVZZWHJBdmV5Z0h3aTZVeGJ3?oc=5","date":"2025-05-28","type":"regulatory","source":"Yicai Global","summary":"China Approves New Insomnia Therapy From Japanese Drugmaker Eisai - Yicai Global","headline":"China Approves New Insomnia Therapy From Japanese Drugmaker Eisai","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9xWlI3dS1abGxrVDRSTVFsWkRydkJBWDFyTkJFYUl3ZGotc0lGTkw3VzJwMVdSTEZYLXZPZ1lWX19PNlZTcDAzQjVJY0tKSjc0bzZWeTgzZVppLTI4dWZ3?oc=5","date":"2025-03-05","type":"pipeline","source":"Nature","summary":"Leveraging deep neural network and language models for predicting long-term hospitalization risk in schizophrenia - Nature","headline":"Leveraging deep neural network and language models for predicting long-term hospitalization risk in schizophrenia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE9QX0M3YXRuWndvak82ZXNnNi14QTJNN0FSajliOUV2RFRGMzBvS2JRT0I5VkNsZEJ0UVJGdWRwejRLdzIxOG9BYkx2RjVLam03azZpV1RWRjhVT1R0TXJVUFFqcU5nQXdTZVZn?oc=5","date":"2025-02-02","type":"pipeline","source":"Wiley Online Library","summary":"Intra- and Extracellular White Matter Micromorphology Predict the Antidepressant Effects of Transcranial Magnetic Stimulation in Patients With Major Depressive Disorder - Wiley Online Library","headline":"Intra- and Extracellular White Matter Micromorphology Predict the Antidepressant Effects of Transcranial Magnetic Stimul","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPNlNiM1FyOFg1YWxwS2oyVjBtSmJJdVplWUlDazdHd3dibEFIaGVSMWhTTlkxN2JoSDBaMndmZDFtdEtPU1gyQ3Bya1RDSkJMblUyNXExR1IzSGxUeS1HeUNqRGdFOXdOSmtaZk52NE1zM3lpQ0I5U09NMWh6VkI1UkhTV3Z0VlQ2MURYbFpRV2MxVDdFLVlpdzdONGtXNzMtaWVVMDRqeGNTQQ?oc=5","date":"2025-01-01","type":"pipeline","source":"Reuters","summary":"China Health Commission to narrow gaps in mental health services - Reuters","headline":"China Health Commission to narrow gaps in mental health services","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxNVG1adnZpbjdYaF96YkxqTE8wdFBlTWpJLVJNRjdKM3oyWU9WSTc3OUV3RnFjVlpkbUVrSjNVbU1scnIzekRXN1RJbnY3MDVrem00ZXhyM1BzN0VUcll4X09DYTItaFZqMmk1QUk4OHpKWHh5bzJLVTJ6MnFOdVN5eGFmQ1Q5a01UY3VsaG0zdlhaMVJBZVE1RGw1RVpaYVkySzd6MFZHNnJwYWRsQkJHQXRjQWhkUmhJYlFjQkRlRkM5S1k3QVBHdWF0ZGtUeUk?oc=5","date":"2024-11-06","type":"pipeline","source":"Advent International","summary":"Beyond the prescription: Genoa Healthcare pioneering pharmacy services in the US - Advent International","headline":"Beyond the prescription: Genoa Healthcare pioneering pharmacy services in the US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOZEh3VTFKRDNfTTl0V0xpcC1jT0plQ3JDUUZRQUxyQUhDUk1UOU5TS1FkTW81cTFuS2RkV3llbGJPTFdDZDVqa3FPOW1aTGRYWXZPSTJIVk8zd3hCcHY1SG1jSlBic3NPRkRWTlUtSG0talRqQkNqWEkxeXRPVXlvVWoxR1dpejhOSHJ1MGUtTEJaSjNwejNIR2Z0V3hzeFhPNjFadU05RUtlTU9haFVseg?oc=5","date":"2024-09-11","type":"deal","source":"Dao Insights","summary":"Prescription coffee? Yongpu and Shanghai Mental Health Center launch collaboration - Dao Insights","headline":"Prescription coffee? Yongpu and Shanghai Mental Health Center launch collaboration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQVTVEOS1iSkRsakkzZjJSeDlZTHdqQWJXaGJiTUQ2MTZqUlJjZVV1aDJ6RU4wY2pXVEgxZTFNc004NmdEeVZKRUQyZkxBQzFXRGkxYXBjWmlRUldhSVVsd1p4QzdmY0xGaDVheFlYSVhQYTQ3Q3J4bkZIVWhyLVlPdURKTWtBeGZlUnNpOUY1c1lHbFl2MEJlQlhRS3BuUWNoTC1N?oc=5","date":"2024-07-10","type":"pipeline","source":"Dao Insights","summary":"Shanghai Mental Health Center hosts art exhibition for eating disorders - Dao Insights","headline":"Shanghai Mental Health Center hosts art exhibition for eating disorders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQcFNGYUV4anFBRmphSkhkY3BsVTlCdzk3ZFhUNEtoOXNwczQtRFJtVTMxRU9qNHZNakVFWHFHTmlFR1VjNkVIb1RtT0ZvdXZxb2daanU4Zjhxano4Z2YyeG1INHJPVDlldDZPWms4TEp6UUpBZDB4NlF3Q2VaNTUtbjFkRVg4Y1MtM2ZNdWF2UlNlOThZQVZUeTBsRnZCazZfenJidWp2SEJvMzZZdGh1Y1lUVFhjQkhoSkcyb3ZiUVlMWlNPa0RWNQ?oc=5","date":"2024-06-04","type":"pipeline","source":"dovepress.com","summary":"NDT - dovepress.com","headline":"NDT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOemdfSUFzenlyc3huWFFpUHJNcW9KeHZsMHotR1oyNTg5OXhKV0V6eGFCUGoxek1DNUZMM0dqcHd3djdCT1F6YmxTWjVGTnRTUllqTnJDT00tUTIxQ09nMXdkTVp2MHhpNzcwQXRhaDZSOWtrV0FWQ3NFbTl3NC13Zmd3czFJOUlDWlBQR1otY0Y?oc=5","date":"2021-03-10","type":"pipeline","source":"Frontiers","summary":"Lower Health Literacy of Mania Than Depression Among Older People: A Random Survey of a Community Healthcare Service Center - Frontiers","headline":"Lower Health Literacy of Mania Than Depression Among Older People: A Random Survey of a Community Healthcare Service Cen","sentiment":"neutral"}],"patents":[],"drugCount":31,"phaseCounts":{"phase_2":7,"marketed":12,"phase_3":12},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}